Skip to main content
NASDAQ:ALLO

Allogene Therapeutics Competitors

$27.50
+0.56 (+2.08 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.90
$28.11
50-Day Range
$26.94
$35.80
52-Week Range
$24.85
$55.00
Volume1.26 million shs
Average Volume875,004 shs
Market Capitalization$3.89 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.28

Competitors

Allogene Therapeutics (NASDAQ:ALLO) Vs. ARGX, QGEN, NVAX, RGEN, NBIX, and CRSP

Should you be buying ALLO stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Allogene Therapeutics, including argenx (ARGX), QIAGEN (QGEN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX), and CRISPR Therapeutics (CRSP).

argenx (NASDAQ:ARGX) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Risk & Volatility

argenx has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Allogene Therapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.

Insider & Institutional Ownership

54.2% of argenx shares are held by institutional investors. Comparatively, 59.9% of Allogene Therapeutics shares are held by institutional investors. 31.3% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares argenx and Allogene Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
argenx$78.17 million178.72$-182,520,000.00($4.73)-57.57
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-15.03

argenx has higher revenue and earnings than Allogene Therapeutics. argenx is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares argenx and Allogene Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
argenxN/AN/AN/A
Allogene TherapeuticsN/A-27.59%-24.97%

Analyst Recommendations

This is a breakdown of recent recommendations for argenx and Allogene Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
argenx071102.61
Allogene Therapeutics031302.81

argenx currently has a consensus target price of $297.8750, suggesting a potential upside of 9.39%. Allogene Therapeutics has a consensus target price of $53.4545, suggesting a potential upside of 94.38%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than argenx.

Summary

Allogene Therapeutics beats argenx on 8 of the 12 factors compared between the two stocks.

QIAGEN (NYSE:QGEN) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Risk & Volatility

QIAGEN has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.

Insider and Institutional Ownership

43.6% of QIAGEN shares are held by institutional investors. Comparatively, 59.9% of Allogene Therapeutics shares are held by institutional investors. 9.0% of QIAGEN shares are held by company insiders. Comparatively, 31.3% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares QIAGEN and Allogene Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QIAGEN$1.53 billion6.99$-41,460,000.00$1.4332.71
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-15.03

QIAGEN has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares QIAGEN and Allogene Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
QIAGEN11.18%17.51%8.44%
Allogene TherapeuticsN/A-27.59%-24.97%

Analyst Ratings

This is a summary of recent recommendations and price targets for QIAGEN and Allogene Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
QIAGEN05902.64
Allogene Therapeutics031302.81

QIAGEN presently has a consensus target price of $60.76, suggesting a potential upside of 29.88%. Allogene Therapeutics has a consensus target price of $53.4545, suggesting a potential upside of 94.38%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than QIAGEN.

Summary

QIAGEN beats Allogene Therapeutics on 7 of the 13 factors compared between the two stocks.

Novavax (NASDAQ:NVAX) and Allogene Therapeutics (NASDAQ:ALLO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Risk & Volatility

Novavax has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.

Insider and Institutional Ownership

49.9% of Novavax shares are held by institutional investors. Comparatively, 59.9% of Allogene Therapeutics shares are held by institutional investors. 3.3% of Novavax shares are held by company insiders. Comparatively, 31.3% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Novavax and Allogene Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$18.66 million522.91$-132,690,000.00($5.80)-22.71
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-15.03

Novavax has higher revenue and earnings than Allogene Therapeutics. Novavax is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novavax and Allogene Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novavax-133.10%-1,346.17%-45.85%
Allogene TherapeuticsN/A-27.59%-24.97%

Analyst Ratings

This is a summary of recent recommendations and price targets for Novavax and Allogene Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novavax11402.50
Allogene Therapeutics031302.81

Novavax presently has a consensus target price of $216.3333, suggesting a potential upside of 64.27%. Allogene Therapeutics has a consensus target price of $53.4545, suggesting a potential upside of 94.38%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Novavax.

Summary

Allogene Therapeutics beats Novavax on 10 of the 13 factors compared between the two stocks.

Repligen (NASDAQ:RGEN) and Allogene Therapeutics (NASDAQ:ALLO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Risk & Volatility

Repligen has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.

Insider and Institutional Ownership

84.3% of Repligen shares are held by institutional investors. Comparatively, 59.9% of Allogene Therapeutics shares are held by institutional investors. 1.7% of Repligen shares are held by company insiders. Comparatively, 31.3% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Repligen and Allogene Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repligen$270.24 million34.94$21.41 million$1.07160.71
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-15.03

Repligen has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Repligen and Allogene Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Repligen13.40%6.58%5.00%
Allogene TherapeuticsN/A-27.59%-24.97%

Analyst Ratings

This is a summary of recent recommendations and price targets for Repligen and Allogene Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Repligen00503.00
Allogene Therapeutics031302.81

Repligen presently has a consensus target price of $222.75, suggesting a potential upside of 29.54%. Allogene Therapeutics has a consensus target price of $53.4545, suggesting a potential upside of 94.38%. Given Allogene Therapeutics' higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Repligen.

Summary

Repligen beats Allogene Therapeutics on 9 of the 13 factors compared between the two stocks.

Neurocrine Biosciences (NASDAQ:NBIX) and Allogene Therapeutics (NASDAQ:ALLO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Risk & Volatility

Neurocrine Biosciences has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.

Valuation and Earnings

This table compares Neurocrine Biosciences and Allogene Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$788.10 million11.35$37.01 million$0.39242.56
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-15.03

Neurocrine Biosciences has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 59.9% of Allogene Therapeutics shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 31.3% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Neurocrine Biosciences and Allogene Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neurocrine Biosciences8.96%18.18%9.50%
Allogene TherapeuticsN/A-27.59%-24.97%

Analyst Ratings

This is a summary of recent recommendations and price targets for Neurocrine Biosciences and Allogene Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neurocrine Biosciences071302.65
Allogene Therapeutics031302.81

Neurocrine Biosciences presently has a consensus target price of $127.8333, suggesting a potential upside of 35.13%. Allogene Therapeutics has a consensus target price of $53.4545, suggesting a potential upside of 94.38%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Neurocrine Biosciences.

Summary

Neurocrine Biosciences beats Allogene Therapeutics on 8 of the 12 factors compared between the two stocks.

Allogene Therapeutics (NASDAQ:ALLO) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Volatility and Risk

Allogene Therapeutics has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500.

Earnings and Valuation

This table compares Allogene Therapeutics and CRISPR Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-15.03
CRISPR Therapeutics$289.59 million27.90$66.86 million$1.1791.15

CRISPR Therapeutics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

59.9% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 66.4% of CRISPR Therapeutics shares are held by institutional investors. 31.3% of Allogene Therapeutics shares are held by insiders. Comparatively, 17.1% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Allogene Therapeutics and CRISPR Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Allogene TherapeuticsN/A-27.59%-24.97%
CRISPR Therapeutics-273.10%-20.72%-18.35%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Allogene Therapeutics and CRISPR Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allogene Therapeutics031302.81
CRISPR Therapeutics231402.63

Allogene Therapeutics presently has a consensus price target of $53.4545, suggesting a potential upside of 94.38%. CRISPR Therapeutics has a consensus price target of $160.8750, suggesting a potential upside of 50.86%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.

Summary

CRISPR Therapeutics beats Allogene Therapeutics on 8 of the 13 factors compared between the two stocks.


Allogene Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
argenx logo
ARGX
argenx
1.1$272.30+4.0%$13.97 billion$78.17 million-57.57News Coverage
QIAGEN logo
QGEN
QIAGEN
1.7$46.78+0.6%$10.67 billion$1.53 billion57.75
Novavax logo
NVAX
Novavax
1.8$131.69+8.1%$9.76 billion$18.66 million-25.23Earnings Announcement
Analyst Report
Analyst Revision
Repligen logo
RGEN
Repligen
1.9$171.96+1.3%$9.44 billion$270.24 million209.71Analyst Report
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$94.60+2.8%$8.94 billion$788.10 million101.72Analyst Report
Unusual Options Activity
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$106.64+5.3%$8.08 billion$289.59 million-32.71Analyst Upgrade
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$126.09+2.2%$7.65 billion$73.99 million-48.68
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$76.70+6.8%$7.21 billion$10.68 million-41.68
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$53.90+4.1%$6.53 billion$26.68 million-24.39
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$43.03+2.9%$6.13 billion$195.99 million268.94Earnings Announcement
Analyst Downgrade
Insider Selling
Analyst Revision
News Coverage
Vir Biotechnology logo
VIR
Vir Biotechnology
1.4$42.21+6.3%$5.49 billion$8.09 million-17.89
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$34.54+2.7%$4.85 billion$85.07 million-36.36Analyst Report
Insider Selling
China Biologic Products logo
CBPO
China Biologic Products
0.8$119.99+1.7%$4.72 billion$503.70 million33.52Upcoming Earnings
Twist Bioscience logo
TWST
Twist Bioscience
1.6$92.68+4.9%$4.53 billion$90.10 million-24.71Analyst Revision
Gap Up
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$71.92+8.0%$4.50 billion$20,000.00-5.12Earnings Announcement
Analyst Report
Analyst Revision
Kodiak Sciences logo
KOD
Kodiak Sciences
1.7$84.05+4.4%$4.31 billionN/A-36.23Earnings Announcement
Analyst Upgrade
Analyst Revision
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.9$25.82+3.1%$3.95 billionN/A-13.45Analyst Revision
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$73.10+6.5%$3.59 billionN/A-42.01Analyst Downgrade
News Coverage
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$29.19+5.8%$2.64 billionN/A0.00Earnings Announcement
Vericel logo
VCEL
Vericel
1.1$50.77+5.7%$2.35 billion$117.85 million-5,077,000.00Analyst Report
Insider Selling
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$31.99+3.9%$2.35 billion$50.04 million0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.5$25.55+7.8%$2.28 billionN/A-11.94Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$12.84+6.9%$2.28 billion$48.83 million-16.89
Editas Medicine logo
EDIT
Editas Medicine
1.6$33.22+5.5%$2.25 billion$20.53 million-19.09
NanoString Technologies logo
NSTG
NanoString Technologies
1.7$49.30+1.8%$2.23 billion$125.57 million-28.83Earnings Announcement
Analyst Report
Insider Selling
Gap Up
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.9$45.52+0.3%$2.05 billionN/A0.00Insider Selling
bluebird bio logo
BLUE
bluebird bio
1.8$30.32+3.3%$2.05 billion$44.67 million-2.76
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$6.62+4.1%$1.90 billion$31.43 million-4.53
Ocugen logo
OCGN
Ocugen
1.0$8.75+5.9%$1.73 billionN/A-5.91Earnings Announcement
Analyst Upgrade
Insider Selling
Replimune Group logo
REPL
Replimune Group
1.5$35.05+1.0%$1.63 billionN/A-19.80
AlloVir logo
ALVR
AlloVir
1.5$24.00+6.9%$1.56 billionN/A0.00Analyst Report
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.85+4.1%$1.56 billion$102.43 million-18.08Analyst Revision
REGENXBIO logo
RGNX
REGENXBIO
1.6$36.14+2.4%$1.54 billion$35.23 million-14.57Analyst Upgrade
News Coverage
Immunovant logo
IMVT
Immunovant
1.6$15.50+5.7%$1.52 billionN/A-12.02Unusual Options Activity
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$67.93+7.9%$1.51 billionN/A-45.90Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$34.84+2.2%$1.50 billionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Alector logo
ALEC
Alector
1.3$17.00+8.8%$1.36 billion$21.22 million-7.62News Coverage
Translate Bio logo
TBIO
Translate Bio
1.6$17.16+4.7%$1.29 billion$7.80 million-16.04
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$26.75+6.9%$1.27 billion$100.56 million0.00News Coverage
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$14.99+1.8%$1.26 billionN/A-3.24Analyst Report
News Coverage
Curis logo
CRIS
Curis
1.3$13.57+3.7%$1.24 billion$10 million-16.55Earnings Announcement
Analyst Report
Unusual Options Activity
News Coverage
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.13+8.2%$1.15 billion$356.07 million7.42Analyst Report
Cortexyme logo
CRTX
Cortexyme
1.1$36.77+6.6%$1.09 billionN/A-15.32Earnings Announcement
Analyst Upgrade
Insider Selling
News Coverage
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$27.50+3.4%$994.46 millionN/A-4.55Earnings Announcement
Insider Selling
Analyst Revision
News Coverage
Vaxcyte logo
PCVX
Vaxcyte
1.7$19.24+0.8%$988.53 millionN/A0.00Earnings Announcement
Scholar Rock logo
SRRK
Scholar Rock
1.5$27.92+1.9%$960.25 million$20.49 million-11.59Earnings Announcement
News Coverage
Gap Up
Sutro Biopharma logo
STRO
Sutro Biopharma
1.5$19.68+4.3%$907.50 million$42.74 million-218.67Analyst Revision
News Coverage
Mesoblast logo
MESO
Mesoblast
1.4$6.99+3.7%$906.88 million$32.16 million-7.94
Passage Bio logo
PASG
Passage Bio
1.8$15.50+1.9%$836.64 millionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.41+2.6%$816.41 million$69.89 million-4.16
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.